WAT Medical Enterprise Unveils HeadaTerm 2 at the American Headache Society's 66th Annual Scientific Meeting

WAT Medical proudly introduced HeadaTerm 2, an innovative wearable anti-migraine device, at the American Headache Society's 66th Annual Scientific Meeting, held in San Diego, California. The device has recently received FDA approval for over-the-counter (OTC) use. This landmark achievement positions HeadaTerm 2 as one of the few non-drug medical devices available in the U.S. without the need for a doctor's prescription.


The HeadaTerm 2 device represents a groundbreaking advancement in migraine treatment. Designed to provide effective relief from migraine symptoms, this wearable device offers a non-pharmaceutical solution for individuals suffering from migraines. The FDA's approval for OTC use underscores the safety and efficacy of HeadaTerm 2, making it more accessible to a broader range of migraine sufferers in the United States.

The debut of HeadaTerm 2 at the scientific meeting generated significant excitement among attendees, including doctors, researchers, and representatives from various non-profit organizations. Many expressed keen interest in the device and its potential to revolutionize migraine treatment. The positive reception highlights the medical community's recognition of the importance of innovative, non-drug solutions for managing migraines.

The American Headache Society (AHS) is committed to improving the lives of people affected by headaches and migraines through education, research, and advocacy. The AHS, in collaboration with its sister organization, the American Migraine Foundation (AMF), plays a crucial role in advancing the understanding and treatment of migraine disorders. The AMF focuses on supporting research and providing resources for patients and healthcare professionals to better manage migraines.


WAT Medical Enterprise is dedicated to collaborating with healthcare providers to deliver safe, effective, and accessible solutions for migraine relief. The introduction of HeadaTerm 2 in the U.S. market marks a pivotal step in this mission. By working closely with medical professionals, WAT Medical aims to enhance the quality of life for individuals affected by migraines and contribute to the advancement of migraine treatment options.

Comprehensive product information and purchase options can be found on the product’s official website and Amazon. Stay tuned for more updates on the progress of HeadaTerm 2 and WAT Medical Enterprise's ongoing efforts to improve migraine management.

Back to blog

Leave a comment

Please note, comments need to be approved before they are published.